Ronald de Wit
Erasmus MC(NL)Erasmus MC Cancer Institute(NL)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Radiopharmaceutical Chemistry and Applications, Testicular diseases and treatments
Most-Cited Works
- → Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer(2004)5,695 cited
- → Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy(2012)4,537 cited
- → Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma(2017)3,353 cited
- → First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study(2017)1,329 cited
- → Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study(2008)1,138 cited
- → The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group